All Outputs (3)

Practical considerations of dissolved oxygen levels for platelet function under hypoxia (2021)
Journal Article
Kusanto, B., Gordon, A., Naylor-Adamson, L., Atkinson, L., Coupland, C., Booth, Z., …Arman, M. (2021). Practical considerations of dissolved oxygen levels for platelet function under hypoxia. International Journal of Molecular Sciences, 22(24), Article 13223. https://doi.org/10.3390/ijms222413223

Investigating human platelet function in low-oxygen environments is important in multiple settings, including hypobaric hypoxia (e.g., high altitude), sea level hypoxia-related disease, and thrombus stability. These studies often involve drawing bloo... Read More about Practical considerations of dissolved oxygen levels for platelet function under hypoxia.

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia (2021)
Thesis
Naylor-Adamson, L. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4224129

Ibrutinib is highly effective in the treatment of chronic lymphocytic leukaemia (CLL), disrupting B cell receptor signalling through the inhibition of Bruton’s tyrosine kinase (Btk). However, ibrutinib has off-target effects, inhibiting platelet aggr... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia.